Study Description: The purpose of this study is to measure the effect of a drug called olanzapine to prevent nausea and vomiting in patients receiving a chemotherapy regimen that has the potential to cause significant nausea and/or vomiting. This study will compare adding olanzapine to standard medications compared to adding a placebo tablet. Paticipants that take part in this study, will be assigned one of two groups. One group will receive olanzapine in addition to standard nausea medications and the other group will receive placebo plus standard nausea medications. Olanzapine or placebo will be given to you in tablet form once a day. We are trying to see if the addition of olanzapine will decrease nausea and vomiting.
Principal Investigator: Amber Clemmons
Eligibility Criteria: Patients are eligable for this study if they are greater than 18 years old and are planning to undergo chemotherpy for a hematologic malignancy. Their chemotherapy must classify as a regimen that is prone to causing nausea and/or vomiting. Patients will be excluded from the study if they are pregnant, allergic to olanzapine, a chronic alcoholic, or have experienced vomiting within 24 hours of starting chemotherapy.
Compensation: No, subjects will not be compensated.
If you don't see specific studies that interest you, please submit your contact information for future studies.